funding to further develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology. Called NGoXIM, the vaccine is based on gonococcal OMVs combined with ...

The Food and Drug Administration (FDA) has approved Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine ... NHBA, and OMV). Noninferiority was observed with Penmenvy vs 2 doses of Bexsero ...

While the MCC experience highlights the potential indirect effects that can be achieved with meningococcal vaccines, it is not advisable to extrapolate the effects of this vaccine to others ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).